Literature DB >> 26408009

Liver cirrhosis in selected autoimmune diseases: a nationwide cohort study in Taiwan.

Chien-Hsueh Tung1,2, Ning-Seng Lai3,4, Ming-Chi Lu3,4, Ching-Chih Lee5,4,6.   

Abstract

The association between autoimmune diseases and liver cirrhosis has rarely been explored in Asian populations, an endemic area of viral hepatitis. The aim of this study was to investigate the comparative risk of liver cirrhosis among a group of selective autoimmune diseases in Taiwanese patients and to identify groups of high risk. This retrospective study was a nationwide, population-based study and used Taiwan's National Health Insurance Research Database. A total of 29,856 patients with definite diagnosis of selected autoimmune diseases (Registry of Taiwan Catastrophic Illness Database, ACR classification) at the starting time point of January 1, 2005, were enrolled in this study. After tracked for a 5-year period, the endpoints were diagnosis of liver cirrhosis (in accordance with International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9-CM codes 571). The control group was composed of other patients in the same database and consisted of randomly selected 753,495 sex- and age-matched non-autoimmune disease patients. The Cox proportional hazard regression model was used to calculate the risk of liver cirrhosis after adjusting for certain variables such as comorbidity, living area, and socioeconomic status. Among the patients with selected autoimmune diseases, 1987 liver cirrhosis were observed. Patients with psoriasis had a significantly increased risk of liver cirrhosis (HR 1.87, 95 % CI 1.25-2.81) than control group without psoriasis. The risk of liver cirrhosis was significantly lower in patients with rheumatoid arthritis (HR 0.29, 95 % CI 0.19-0.44). There is a gradient of risk of liver cirrhosis among the autoimmune diseases; the specific risks need to be investigated on the basis of hypotheses. Conventional immunosuppressive drug administration should be carefully implemented by regular monitoring of liver condition in order to avoid causing an adverse effect of chronic liver fibrosis.

Entities:  

Keywords:  Autoimmune; Liver cirrhosis; Psoriasis; Rheumatoid arthritis

Mesh:

Year:  2015        PMID: 26408009     DOI: 10.1007/s00296-015-3369-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  28 in total

1.  Assessment of liver fibrosis by transient elastography in rheumatoid arthritis patients treated with methotrexate.

Authors:  Sung-Hoon Park; Jung-Yoon Choe; Seong-Kyu Kim
Journal:  Joint Bone Spine       Date:  2010-05-14       Impact factor: 4.929

2.  Psoriatic arthritis, methotrexate and the liver--are rheumatologists putting their patients at risk?

Authors:  K Lindsay; A Gough
Journal:  Rheumatology (Oxford)       Date:  2008-05-12       Impact factor: 7.580

Review 3.  Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?

Authors:  James A Thomas; Guruprasad P Aithal
Journal:  Am J Clin Dermatol       Date:  2005       Impact factor: 7.403

4.  Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients.

Authors:  Charlie Laohapand; Emvalee Arromdee; Tawesak Tanwandee
Journal:  Hepatol Int       Date:  2015-01-15       Impact factor: 6.047

5.  Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis--short- and long-term toxicity in 104 patients.

Authors:  U Wollina; K Ständer; U Barta
Journal:  Clin Rheumatol       Date:  2001       Impact factor: 2.980

Review 6.  Liver abnormalities in connective tissue diseases.

Authors:  Maria De Santis; Chiara Crotti; Carlo Selmi
Journal:  Best Pract Res Clin Gastroenterol       Date:  2013-08       Impact factor: 3.043

7.  The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis.

Authors:  J M Kremer; J K Lee
Journal:  Arthritis Rheum       Date:  1986-07

8.  Hepatitis C virus infection as a risk factor for non-alcoholic liver cirrhosis in Taiwan.

Authors:  J F Tsai; W Y Chang; J E Jeng; M S Ho; L Y Wang; M Y Hsieh; S C Chen; W L Chuang; Z Y Lin; J H Tsai
Journal:  J Med Virol       Date:  1993-12       Impact factor: 2.327

9.  Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology.

Authors:  J M Kremer; G S Alarcón; R W Lightfoot; R F Willkens; D E Furst; H J Williams; P B Dent; M E Weinblatt
Journal:  Arthritis Rheum       Date:  1994-03

Review 10.  Management of rheumatic disease with comorbid HBV or HCV infection.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Nat Rev Rheumatol       Date:  2012-05-08       Impact factor: 20.543

View more
  2 in total

1.  Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registry-based study.

Authors:  Ching-Chieh Yang; Hung-Chang Wu; Shou-Sheng Chu; Yu-Hsuan Kuo; Wen-Shan Liu; Shih-Chang Wang; Chung-Han Ho; Yi-Chen Chen
Journal:  Sci Rep       Date:  2021-01-15       Impact factor: 4.379

2.  Antitumour necrosis factor-α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort.

Authors:  Kuo-Tung Tang; Jean-François Dufour; Po-Hung Chen; Ruben Hernaez; Susan Hutfless
Journal:  BMJ Open Gastroenterol       Date:  2020-04-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.